Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Epelsiban

Phase 2Small molecule

Epelsiban is one of 21 small molecule programs targeting Adenomyosis. It is currently in Phase 2.

1

Indications

4

Total Trials

0

Active Trials

20

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

AdenomyosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Adenomyosis

#DrugCompanyPhaseTrials

Femara

Bayer Aspirin

Zoladex

TTerSera Therapeutics LLC

Prometrium

Ofev

Boehringer Ingelheim

Gnrh Agonist

Johnson & Johnson

Enantone

Mifeprex

Gnrh Analog

MMemorial Sloan Kettering Cancer Center

Ulipristal Acetate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Women1 trial

Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers

Completed· GSK logo

GSK·Phase 1·NCT02703181·31 enrolled

Female1 trial

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

Completed· GSK logo

GSK·Phase 1·NCT02257359·12 enrolled

Adenomyosis1 trial

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

Withdrawn· GSK logo

GSK·Phase 2·NCT02794467

Concentration1 trial

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Terminated· GSK logo

GSK·Phase 1·NCT02213029·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Epelsiban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epelsiban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epelsiban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Related News